Total Payments
$11,522
2024 Payments
$887.73
Companies
12
Transactions
33
Medicare Patients
961
Medicare Billing
$130,636
Payment Breakdown by Category
Consulting$6,725 (58.4%)
Research$1,953 (17.0%)
Travel$1,551 (13.5%)
Food & Beverage$1,263 (11.0%)
Education$29.99 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $6,725 | 1 | 58.4% |
| Unspecified | $1,953 | 6 | 17.0% |
| Travel and Lodging | $1,551 | 5 | 13.5% |
| Food and Beverage | $1,263 | 20 | 11.0% |
| Education | $29.99 | 1 | 0.3% |
Payments by Type
General
$9,569
27 transactions
Research
$1,953
6 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eisai Inc. | $8,196 | 12 | $0 (2019) |
| Eli Lilly and Company | $1,773 | 5 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $772.70 | 3 | $0 (2024) |
| Genentech USA, Inc. | $242.24 | 2 | $0 (2022) |
| Avid Radiopharmaceuticals, Inc. | $180.00 | 1 | $0 (2017) |
| Life Molecular Imaging Ltd | $92.89 | 2 | $0 (2024) |
| Biogen, Inc. | $63.47 | 1 | $0 (2019) |
| Lilly USA, LLC | $63.17 | 2 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $60.27 | 2 | $0 (2022) |
| Allergan Inc. | $29.99 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $887.73 | 7 | E.R. Squibb & Sons, L.L.C. ($772.70) |
| 2023 | $418.73 | 2 | Eli Lilly and Company ($355.00) |
| 2022 | $1,383 | 6 | Eli Lilly and Company ($1,147) |
| 2020 | $271.35 | 2 | Eli Lilly and Company ($271.35) |
| 2019 | $8,352 | 14 | Eisai Inc. ($8,196) |
| 2018 | $29.99 | 1 | Allergan Inc. ($29.99) |
| 2017 | $180.00 | 1 | Avid Radiopharmaceuticals, Inc. ($180.00) |
All Payment Transactions
33 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/03/2024 | CSL Behring | Haegarda (Biological) | Food and Beverage | In-kind items and services | $28.23 | General |
| Category: Immunology | ||||||
| 07/31/2024 | Lilly USA, LLC | KISUNLA (Drug) | Food and Beverage | In-kind items and services | $37.63 | General |
| Category: Neuroscience | ||||||
| 07/28/2024 | Life Molecular Imaging Ltd | NEURACEQ (Drug) | Food and Beverage | Cash or cash equivalent | $29.16 | General |
| Category: Diagnostic Tracer | ||||||
| 03/29/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | In-kind items and services | $328.37 | General |
| 03/29/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $308.03 | General |
| 03/29/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | In-kind items and services | $136.30 | General |
| 03/28/2024 | Medline Industries LP | — | Food and Beverage | In-kind items and services | $20.01 | General |
| 07/17/2023 | Life Molecular Imaging Ltd | NEURACEQ (Drug) | Food and Beverage | Cash or cash equivalent | $63.73 | General |
| Category: Diagnostic Tracer | ||||||
| 01/30/2023 | Eli Lilly and Company | — | — | In-kind items and services | $355.00 | Research |
| Study: A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) | ||||||
| 12/01/2022 | Genentech USA, Inc. | — | Food and Beverage | In-kind items and services | $149.86 | General |
| 12/01/2022 | Lilly USA, LLC | — | Food and Beverage | In-kind items and services | $25.54 | General |
| 06/23/2022 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $30.80 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 06/02/2022 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $29.47 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 04/29/2022 | Eli Lilly and Company | — | — | In-kind items and services | $697.00 | Research |
| Study: ANTI-AMYLOID TREATMENT IN ASYMPTOMATIC ALZHEIMERS DISEASE -A4 STUDY | ||||||
| 04/29/2022 | Eli Lilly and Company | — | — | In-kind items and services | $450.00 | Research |
| Study: ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | ||||||
| 11/24/2020 | Eli Lilly and Company | — | — | In-kind items and services | $1.35 | Research |
| Study: ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | ||||||
| 07/31/2020 | Eli Lilly and Company | — | — | In-kind items and services | $270.00 | Research |
| Study: ANTI-AMYLOID TREATMENT IN ASYMPTOMATIC ALZHEIMERS DISEASE -A4 STUDY | ||||||
| 12/05/2019 | Biogen, Inc. | — | Food and Beverage | Cash or cash equivalent | $63.47 | General |
| 12/05/2019 | Eisai Inc. | — | Food and Beverage | Cash or cash equivalent | $50.60 | General |
| 07/15/2019 | Genentech USA, Inc. | — | Food and Beverage | In-kind items and services | $92.38 | General |
| 02/08/2019 | Eisai Inc. | — | Consulting Fee | Cash or cash equivalent | $6,725.00 | General |
| 02/08/2019 | Eisai Inc. | — | Travel and Lodging | Cash or cash equivalent | $551.60 | General |
| 02/08/2019 | Eisai Inc. | — | Travel and Lodging | Cash or cash equivalent | $296.20 | General |
| 02/08/2019 | Eisai Inc. | — | Travel and Lodging | Cash or cash equivalent | $238.75 | General |
| 02/08/2019 | Eisai Inc. | — | Food and Beverage | Cash or cash equivalent | $114.83 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ANTI-AMYLOID TREATMENT IN ASYMPTOMATIC ALZHEIMERS DISEASE -A4 STUDY | Eli Lilly and Company | $967.00 | 2 |
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | Eli Lilly and Company | $451.35 | 2 |
| A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) | Eli Lilly and Company | $355.00 | 1 |
| AN OPEN LABEL, MULTICENTER STUDY EVALUATING THE IMAGING CHARACTERISTICS OF A FOLLOW UP 18F-AV-1451 SCAN IN SUBJECTS THAT PARTICIPATED IN THE CONFIRMATORY COHORT OF 18F-AV-1451-A05 | Avid Radiopharmaceuticals, Inc. | $180.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 246 | 293 | $186,775 | $48,038 |
| 2022 | 5 | 255 | 289 | $128,711 | $28,580 |
| 2021 | 5 | 254 | 274 | $119,516 | $31,807 |
| 2020 | 4 | 206 | 231 | $94,267 | $22,210 |
Total Patients
961
Total Services
1,087
Medicare Billing
$130,636
Procedure Codes
21
All Medicare Procedures & Services
21 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 78608 | Nuclear medicine study of brain with metabolic evaluation | Office | 2023 | 15 | 15 | $43,809 | $14,506 | 33.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 60 | 90 | $49,050 | $11,752 | 24.0% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2023 | 20 | 20 | $30,660 | $8,200 | 26.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 53 | 63 | $24,135 | $5,095 | 21.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 33 | 33 | $22,143 | $4,992 | 22.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 42 | 46 | $12,558 | $2,513 | 20.0% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 23 | 26 | $4,420 | $980.64 | 22.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 68 | 86 | $46,870 | $11,610 | 24.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 54 | 54 | $36,202 | $7,838 | 21.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 62 | 69 | $26,706 | $5,362 | 20.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 46 | 52 | $14,224 | $2,730 | 19.2% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 25 | 28 | $4,709 | $1,041 | 22.1% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 70 | 70 | $45,266 | $12,159 | 26.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 64 | 73 | $37,265 | $10,250 | 27.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 55 | 61 | $21,683 | $5,677 | 26.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 49 | 52 | $12,616 | $3,153 | 25.0% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 16 | 18 | $2,686 | $568.86 | 21.2% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 72 | 87 | $38,281 | $8,771 | 22.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 82 | 91 | $29,757 | $6,891 | 23.2% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 36 | 36 | $22,572 | $5,634 | 25.0% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 16 | 17 | $3,657 | $914.19 | 25.0% |
About Dr. Amanda Smith, MD
Dr. Amanda Smith, MD is a Psychiatry healthcare provider based in Tampa, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/18/2006. The National Provider Identifier (NPI) number assigned to this provider is 1316051253.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Amanda Smith, MD has received a total of $11,522 in payments from pharmaceutical and medical device companies, with $887.73 received in 2024. These payments were reported across 33 transactions from 12 companies. The most common payment nature is "Consulting Fee" ($6,725).
As a Medicare-enrolled provider, Smith has provided services to 961 Medicare beneficiaries, totaling 1,087 services with total Medicare billing of $130,636. Data is available for 4 years (2020–2023), covering 21 distinct procedure/service records.
Ad
Practice Information
- Specialty Psychiatry
- Other Specialties Geriatric Psychiatry
- Location Tampa, FL
- Active Since 08/18/2006
- Last Updated 03/31/2025
- Taxonomy Code 2084P0800X
- Entity Type Individual
- NPI Number 1316051253
Products in Payments
- NEURACEQ (Drug) $92.89
- XARELTO (Drug) $60.27
- KISUNLA (Drug) $37.63
- VRAYLAR (Drug) $29.99
- Haegarda (Biological) $28.23
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatry Doctors in Tampa
David Sheehan, Md, MD
Psychiatry — Payments: $716,039
Psychiatry $716,039
Dr. Jamie Fernandez, M.d, M.D
Psychiatry — Payments: $674,462
Psychiatry $674,462
Dr. Kenneth Pages, Md, MD
Psychiatry — Payments: $491,147
Psychiatry $491,147
Dr. Hardeep Singh, Md, MD
Psychiatry — Payments: $403,775
Psychiatry $403,775
Chetan Gandhy, Md, MD
Psychiatry — Payments: $220,445
Psychiatry $220,445
Mr. Brian Gadbois, M.d, M.D
Psychiatry — Payments: $38,094
Psychiatry $38,094